medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Número 1

<< Anterior Siguiente >>

Rev Invest Clin 2005; 57 (1)


Lectinas vegetales y sus efectos en el cáncer

Castillo-Villanueva A, Abdullaev F

Idioma: Español
Referencias bibliográficas: 80
Paginas: 55-64
Archivo PDF: 85.29 Kb.


RESUMEN

La importancia de estudiar compuestos naturales para utilizarlos como opciones médicas terapéuticas, específicamente contra el cáncer, nos da la pauta para realizar una revisión exhaustiva de la literatura concerniente a la actividad biológica de las lectinas vegetales, las cuales han sido reportadas por poseer propiedades tóxicas, citotóxicas, antitumorales y anticancerígenas. En este trabajo revisamos diferentes estudios publicados sobre el mecanismo de acción de las lectinas con respecto a su efecto antitumoral.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Goldstein IJ, Hughes RS, Monsigny M, Osawa T, Sharon N. What should be called a lectin? Nature 1980; 285: 665-6.

  2. Hernández DP, Martín GO, Rodríguez PV, Ganem BF. Aplicaciones de las lectinas. Rev Cubana Hematol Inmunol Hemoter 1999; 15: 91-5.

  3. Pusztai AJ. Plant lectins. Cambridge: Cambridge University Press, 1991.

  4. Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology 2004; 14(11): 53R-62R.

  5. Lajolo FM, Genoves MI. Nutritional significance of lectins and enzyme inhibitors from legumes. J Agric Food Chem 2002; 50(22): 6592-8.

  6. Sharon N, Lis H. Lectins-proteins with a sweet tooth: functions in cell recognition. Essays Biochem 1995; 30: 59-75.

  7. Ohba H, Moriwaki S, Bakalova R, Yasuda S, Yamasaki N. Plant-derived abrin-a induces apoptosis in cultured leukemic cell lines by different mechanism. Toxicol Appl Pharmacol 2004: 195(2): 182-93.

  8. Aub JC, Tieslau C, Lankester A. Reactions of normal and tumor cell surfaces to enzymes. I. Wheat germ lipase and associated mucopolysaccharides. Proc Natl Acad Sci USA 1963; 50: 613-9.

  9. Guillot J, Guerry M, Konska G, Caldefie-Chezet F, De Latour M, Penault-Llorca F. Modification of glycoconjugates during the carcinogenesis: the case of mammary carcinomas. Bull Cancer 2004; 91(2): 141-58.

  10. Gabius HJ, Probing the cons and pros of lectin-induced immunomodulation: case studies for the mistletoe lectin and galectin-1. Biochimie 2001; 83(7): 659-66.

  11. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004; 95(5): 377-84.

  12. Kobata A. A retrospective and prospective view of glycopathology. Glycoconjugates J 1998; 15: 323-31.

  13. Gabius HJ, Gabius S. Glycosciences: status and perspectives. London: Chapman and Hall; 1997.

  14. Fan X, She YM, Bagshaw RD, Callahan JW, Schachter H, Mahuran DJ. A method for proteomic identification of membrane-bound proteins containing Asn-linked oligosaccharides. Anal Biochem 2004; 332(1): 178-86.

  15. Hakomori S. Cancer-associated glycosphingolipid antigens: their structure, organization and function. Acta Anat 1998; 161: 79-90.

  16. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 1996; 179: 358-69.

  17. Kitamura N, Guo S, Sato T, Hiraizumi S, Taka J, Ikekita M, Sawada S, Fujisawa H, Furukawa K. Pronostic significance of reduced expression of beta-N-acetylgalactosaminylated N-linked oligosaccharides in human breast cancer. Int J Cancer 2003; 105(4): 533-41.

  18. Abdullaev FI, González de Mejía E. Antitumor effect of plant lectins. Natural toxins 1997; 5: 157-63.

  19. Lin JK, Tserng KY, Chen CC, Lin LT, Tung TC. Abrin and ricin: new anti-tumor substances. Nature 1970; 227: 292-3.

  20. Doan LG. Ricin: mechanism of toxicity, clinical manifestations, and vaccine development. J Toxicol Clin Toxicol 2004; 42(2): 201-8.

  21. Dickers KJ, Bradberry SM, Rice P, Griffiths GD, Vale JA. Abrin poisoning. Toxicol Rev 2003; 22(3): 137-42.

  22. Shoham J, Inbar M, Sachs L. Differential toxicity on normal and transformed cells in vitro and inhibition of tumour development in vivo by concanavalin A. Nature 1970; 227: 1244-6.

  23. Chen YF, Boland CR, Kraus ER, Goldstein IJ. The lectin Griffonia simplicifolia I-A4 (GSI-A4) specifically recognizes terminal alpha-linked N-acetylgalactosaminyl groups and is cytotoxic to the human colon cancer cell lines LSII74 and SW1116. Int J Cancer 1994; 57: 561-7.

  24. Knibbs RN, Mac-Callum DK, Lillie JH, Goldstein IJ. Wild-type and cultured Ehrlich ascites tumor cells differ in tumorigenicity, lectin binding pattern and binding to basement membranes. Glycobiology 1994; 4: 419-28.

  25. Ganguly C, Das S. Plant lectins as inhibitors of tumor growth and modulators of host immune response. Chemotherapy 1994; 40: 272-8.

  26. Pryme IF, Pusztai AJ, Bardocz S. A diet containing the lectin phytohaemagglutinin (PHA) slows the proliferation of Krebs II cell tumours in mice. Cancer Lett 1994; 76: 133-7.

  27. Mukhopadhyay P, Gupta JD, Sanyal U, Das S. Influence of dietary restriction and soybean supplementation on the growth of a murine lymphoma and host immune function. Cancer Lett 1994; 78: 151-7.

  28. Wang HX, Ng TB, Ooi VE, Liu WK, Chang ST. Actions of lectins from the mushroom Tricholoma mongolicum on macrophages, splenocytes and life-span in sarcoma-bearing mice. Anticancer Res 1997; 17: 419-24.

  29. Kiss R, Camby I, Duckworth D, De-Decker R, Salmon I et al. In vitro influence of Phaseolus vulgaris, Griffonia simplicifolia, Concanavalin A, wheat germ and peanut agglutinins on HCT-15, LoVo and SW 837 human colorrectal cancer cell growth. Gut 1997; 40: 253-61.

  30. Garbor F, Stangl M, Wirth M. Lectin-mediated bioadhesion: binding characteristics of plant lectins on the enterocyte-like cell lines Caco-2, HT-29 and HCT-8. J Control Release 1998; 55: 131-42.

  31. Parslew R, Jones KT, Rhodes JM, Sharpe GR. The antiproliferative effect of lectin from the edible mushroom (Agarics bisporus) on human keratinocytes: preliminary studies on its use in psoriasis. Br J Dermatol 1999; 140: 56-60.

  32. Litynska A, Przybylo M, Pochec E, Hoja-Lukowicz D, Ciolczyk D, Laidler P, Gil D. Comparison of the lectin-binding pattern in different human melanoma cell lines. Melanoma Res 2001; 11: 205-12.

  33. Maier G, Fiebig HH. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anti-Cancer Drugs 2002; 13: 373-9.

  34. Valantier U, Fabian S, Schumancher U, Leathem AJ. The influence of dietary lectins on the cell proliferation of human breast cancer cell lines in vitro. Anticancer Res 2003; 23(2B): 1197-206.

  35. Lyu SY, Park SM, Choung BY, Park WB. Comparative study of Korean (Viscum album var. coloratum) and European mistletoes (Viscum album). Arch Pharm Res 2000; 23: 592-8.

  36. Schumacher U, Stamouli A, Adam E, Peddie M, Pfuller U. Biochemical, histochemical and cell biological investigations on the actions of mistletoe I, II and III with human breast cancer cell lines. Glycoconj J 1995; 12: 250-7.

  37. Umekawa H, Kondoh K, Furuichi Y, Takahashi T, Yoshida S. DNA polymerase alpha, beta and gamma activities in human lymphocytes stimulated by Tora-mame (Phaseolus vulgaris) lectin. Biochem Int 1992; 28: 1063-70.

  38. Leist M, Wendel A. A novel mechanism of murine hepatocyte death inducible by concanavalin A. J Hepatol 1996; 25: 948-59.

  39. Rocha N, Salazar-Olivo LA, Abdullaev F, González de Mejía E. The hemagglutinating and cytotoxic activities of extracts from Mexican legumes on human tumor cells. In: Whitaker JR, Haard NF, Shoemaker CF, Singh RP (eds.). The proceeding of the 3rd. International Conference Food for Health in the Pacific Rim. Connecticut: Food & Nutrition Press; 1999, p. 420-6.

  40. Jordison M, El-Hariry I, Calnan D, Calam J, Pignatelli M. Vicia faba agglutinin, the lectin present in broad beans, stimulates differentiation of undifferentiated colon cancer cells. Gut 1999; 44: 709-14.

  41. Kent D, Sheridan CM, Tomkinson HA, White SJ, Hiscott P, Yu L, Grierson I. Edible mushroom (Agaricus bisporus) lectin inhibits human retinal pigment epithelial cell proliferation in vitro. Wound repair regen 2003; 11(4): 285-91.

  42. Yu LG, Fernig DG, White MRH, Spiller DG, Appleton P, Evans RC, Grierson I, Smith JA, Davies H, Gerasimenko OV, Petersen OH, Milton JD, Rhodes JM. Edible mushroom (Agaricus bisporus) lectin, which reversibly inhibits epithelial cell proliferation, blocks nuclear localization sequence-dependent nuclear protein import. J Biol Chem 1999; 274: 4890-9.

  43. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S. Mistletoes lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 1999; 59: 2083-90.

  44. Pryme IF, Pustai A, Bardocz S, Ewen SW. A combination of dietary protein depletion and PHA-induced growth gut reduce the mass of murine non-Hodkin lymphoma. Cancer Lett 1999; 139: 145-52.

  45. Pryme IF, Bardocz S, Pusztai A, et al. The growth of an established murine non-Hodkin lymphoma tumour is limited by switching to a phytohaemagglutinin-containing diet. Cancer Lett 1999; 146: 87-91.

  46. Pryme IF, Bardocz S, Pusztai A, et al. Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodkin lymphoma. Histol Histopathol 2002; 17: 261-71.

  47. Lyu SY, Park WB, Choi KH, Kim WH. Involvement of caspase-3 in apoptosis induced by Viscum album var. coloratum agglutinin in HL-60 cells. Biosci Biotechnol Biochem 2001: 65: 534-41.

  48. Park, WB, Lyu SY, Kim JH, Choi SH, Chung HK, Ann SH, Hong SY, Yoon TJ, Choi MJ. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother Radiopharm 2001; 16: 439-47.

  49. Lyu SY, Choi SH, Park WB. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch Pharm Res 2002; 25(1): 1-8.

  50. Yu LG, Andrews N, Weldon M, Gerasimenko OV, Campbell BJ, Singh R, Grierson I, Petersen OH, Rhodes JM. An N-terminal truncated form of Orp 150 is a cytoplasmic ligand for the anti-proliferative mushroom Agaricus bisporus lectin and is required for nuclear localization sequence-dependent nuclear protein import. J Biol Chem 2002; 227: 24538-45.

  51. Sasaki T, Yamazaki K, Yamori T, Endo T. Inhibition of proliferation and induction of differentiation of glioma cells with Datura stramonium agglutinin. Br J Cancer 2002; 87: 918-23.

  52. Ramnath V, Kuttan G, Kuttan R. Antitumor effect of abrin on transplanted tumours in mice. Indian J Physiol Pharmacol 2002; 46(1): 69-77.

  53. Zhao C, Sun H, Tong X, Qi Y. An antitumour lectin from the edible mushroom Agrocybe aegerita. Biochem J 2003; 374: 321-7.

  54. Yoon TJ, Yoo YC, Kang TB, Song SK, Lee KB, Her E, Song KS, Kim JB. Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res 2003; 26: 861-7.

  55. Pryme IF, Bardocz S, Pusztai A, Ewen SW, Pfuller U. A mistletoe lectin (ML-1)-containing diet reduces the viability of a murine non-Hodgkin lymphoma tumor. Cancer Detect Prevent 2004; 28: 52-6.

  56. Olsnes S, Kozlov JV. Ricin. Toxicon 2001; 39(11): 1723-8.

  57. PLANT LECTINS. Disponible en URL: http://www.ansci.cornell.edu/plants/toxicagents/lectins/lectins.html#lecttissu

  58. Vasconcelos IM, Oliveira JT. Antinutritional properties of plant lectins. Toxicon 2004; 44(4): 385-403.

  59. Franz DR, Jaax NK. Ricin toxin. In: Textbook of military medicine: medical aspects of chemical and biological warfare. Washington, DC: TMM Publications, 1997: 631-42.

  60. Stein GM, Berg PA. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Res 1999; 4(5): 169-77.

  61. Huber R, Barth H, Schmitt-Graff A, Klein R. Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Altern Complement Med 2000; 6(4): 305-10.

  62. Huber R, Klein R, Berg PA, Ludtke R, Werner M. Effects of a letin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects. J Altern Complement Med 2002; 8(6): 857-66.

  63. Hutt N, Kopferschmitt-kubler MC, Cabalio J, Purohit A, Alt M, Pauli G. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol 2001; 29(5): 201-3.

  64. Stauder H, Kreuser ED. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 2002; 25(4): 374-80.

  65. Mansky PJ. Mistletoe and cancer: controversies and perspectives. Semin Oncol 2002; 29(6): 589-94.

  66. The Castor Bean: a plant named after a tick. Noteworthy plants for March 1999. Disponible en: URL: Http://waynesword.palomar.edu/plmar99.htm#medicine.

  67. Baluna R, Sausville EA, Stone MJ, Steter-Stevenson MA, Uhr JW, Vitetta ES. Decrease in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. Clin Cancer Res 1996; 2(10): 1705-12.

  68. Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol 1999; 11(5): 570-8.

  69. Schindler J, Sausville E, Messmann R, Uhr JW, Vitetta ES. The toxicity of deglycosylated ricin a chain-containing immunotoxins in patients with non-Hodgkin’s lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 2001; 7(2): 255-8.

  70. Dinndorf P, Krailo M, Liu-Mares W, Frierdich S, Sondel P, Reaman G. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J Immunother 2001; 24(6): 511-6.

  71. Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma. Ann Oncol 2003; 14(5): 729-36.

  72. Nagy M. Ricin-a plant toxin potential therapeutic use. Ceska Slov Farm 2004; 53(3): 131-4.

  73. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 2004; 61(1): 1-11.

  74. Lazaris ACh, Chatzigianni EB, Paraskevakoc H, Tseleni-Balafouta S, Davaris PS. Lectin histochemistry as a predictor of dysplasia grade in colorectal adenomas. Path Oncol Res 2000; 6(4): 265-71.

  75. Sherwani AF, Mohmood S, Khan F, Khan RH, Azfer M A. Characterization of lectins and their specificity in carcinomas- an appraisal. Ind. J Clin Biochem 2003; 18: 169-80.

  76. Choi SH, Lyu SY, Park WB. Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch Pharm Res 2004; 27: 68-76.

  77. Rebbaa A, Chou PM, Vucic I, Mirkin BL, Tomita T, Bremer EG. Expression of bisecting GlcNAc in pediatric brain tumors and its association with tumor cell response to vinblastine. Clin Cancer Res 1999; 5: 3661-8.

  78. Siegle I, Fritz P, McClellan M, Gutzeit S, Murdter TE. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res 2001; 21(4A): 2687-91.

  79. D’Costa SS, Hurwitz JL. Phytohemagglutinin inhibits lymphoid tumor growth in vitro and in vivo. Leuk Lymp 2003; 44: 1785-91.

  80. Abdullaev FI. Plant-derived agents against cancer. In: Gupta SK (ed.). Pharmacology and therapeutics in the new millennium. New Delhi, India. Narosa Publishing House 2001; 30: 345-54.




2020     |     www.medigraphic.com